Univariate and multivariate analyses of progression-free survival
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age, years | 0.99 (0.98–1.01) | 0.211 | - | - |
| Gender (male vs. female) | 0.98 (0.76–1.28) | 0.894 | - | - |
| ECOG (1 vs. 0) | 1.39 (1.07–1.80) | 0.013 | 1.49 (1.14–1.94) | 0.004 |
| ECOG (2 vs. 0) | 1.56 (0.64–3.82) | 0.332 | 1.95 (0.79–4.81) | 0.148 |
| BMI, kg/m2 | 0.98 (0.94–1.03) | 0.473 | - | - |
| Smoking history (yes vs. no) | 0.94 (0.72–1.22) | 0.641 | - | - |
| Drinking history (yes vs. no) | 0.86 (0.63–1.17) | 0.343 | - | - |
| Diabetes history (yes vs. no) | 1.26 (0.96–1.66) | 0.101 | - | - |
| Surgery before chemotherapy (yes vs. no) | 1.09 (0.77–1.56) | 0.619 | - | - |
| Baseline stage (metastatic vs. locally advanced) | 1.80 (1.37–2.37) | < 0.001 | 1.26 (0.84–1.89) | 0.259 |
| Baseline CA19-9 level, U/mL | 1.00 (1.00–1.00) | 0.076 | 1.00 (1.00–1.00) | 0.302 |
| Liver metastases (yes vs. no) | 1.98 (1.52–2.57) | < 0.001 | 1.78 (1.22–2.59) | 0.003 |
| Multiple metastases (yes vs. no) | 1.44 (1.02–2.04) | 0.037 | 1.06 (0.73–1.53) | 0.758 |
| First-line regimen (GS vs. GnP) | 0.82 (0.62–1.08) | 0.157 | - | - |
The bold values indicate P < 0.1 in the univariable analysis and P < 0.05 in the multivariable analysis.